CA2098393A1 - Administration par voie orale d'interferon alpha pour le traitement des tumeurs pulmonaires malignes - Google Patents

Administration par voie orale d'interferon alpha pour le traitement des tumeurs pulmonaires malignes

Info

Publication number
CA2098393A1
CA2098393A1 CA002098393A CA2098393A CA2098393A1 CA 2098393 A1 CA2098393 A1 CA 2098393A1 CA 002098393 A CA002098393 A CA 002098393A CA 2098393 A CA2098393 A CA 2098393A CA 2098393 A1 CA2098393 A1 CA 2098393A1
Authority
CA
Canada
Prior art keywords
treating
preventing
alpha interferon
interferon
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002098393A
Other languages
English (en)
Inventor
Robert J. Spiegel
Francis M. Cuss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2098393A1 publication Critical patent/CA2098393A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002098393A 1990-12-14 1991-12-11 Administration par voie orale d'interferon alpha pour le traitement des tumeurs pulmonaires malignes Abandoned CA2098393A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62824090A 1990-12-14 1990-12-14
US628,240 1990-12-14

Publications (1)

Publication Number Publication Date
CA2098393A1 true CA2098393A1 (fr) 1992-06-15

Family

ID=24518070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002098393A Abandoned CA2098393A1 (fr) 1990-12-14 1991-12-11 Administration par voie orale d'interferon alpha pour le traitement des tumeurs pulmonaires malignes

Country Status (11)

Country Link
EP (1) EP0563177A1 (fr)
JP (1) JPH06503570A (fr)
AU (1) AU9139091A (fr)
CA (1) CA2098393A1 (fr)
EE (1) EE9400337A (fr)
IE (1) IE914326A1 (fr)
IL (1) IL100332A0 (fr)
MX (1) MX9102512A (fr)
PT (1) PT99784A (fr)
WO (1) WO1992010207A1 (fr)
ZA (1) ZA919769B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213322D0 (en) * 1992-06-23 1992-08-05 Efamol Holdings Antioxidant compositions
DE69522492T2 (de) * 1994-04-09 2002-05-23 Hoffmann La Roche Verfahren zur Herstellung von Alpha-Interferon
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
AU724689B2 (en) 1996-05-09 2000-09-28 Pharma Pacific Pty Ltd Method of treatment
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
CN1151840C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备用于治疗哺乳动物肿瘤病的药剂中的应用
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
WO2004000266A1 (fr) * 2002-06-20 2003-12-31 Yuriy Vasilievich Tyagotin Methode d'administration d'interferon par voie orale transmucosale

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
EP0372809B1 (fr) * 1988-12-01 1993-08-04 Schering Corporation Médicament pour le traitement intralésionnel de carcinomes cellulaires squameux avec de l'interféron alpha humain recombinant

Also Published As

Publication number Publication date
IL100332A0 (en) 1992-09-06
EE9400337A (et) 1996-02-15
AU9139091A (en) 1992-07-08
MX9102512A (es) 1992-06-01
EP0563177A1 (fr) 1993-10-06
JPH06503570A (ja) 1994-04-21
PT99784A (pt) 1992-12-31
ZA919769B (en) 1992-09-30
IE914326A1 (en) 1992-06-17
WO1992010207A1 (fr) 1992-06-25

Similar Documents

Publication Publication Date Title
US5618786A (en) Aerosolization of protein therapeutic agent
EP0505123B1 (fr) Administration par voie pulmonaire de G-CSF
US20010041190A1 (en) Method for pulmonary and oral delivery of pharmaceuticals
Knight et al. Ribavirin aerosol treatment of influenza
CA2271126C (fr) Traitement de la bronchite avec des uridine triphosphates et composes associes
EP4138832A1 (fr) Produits de fabrication et procédés de traitement, d'amélioration ou de prévention d'infections microbiennes
Tønnesen et al. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction
Khanna et al. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution
CA2098393A1 (fr) Administration par voie orale d'interferon alpha pour le traitement des tumeurs pulmonaires malignes
CN102716105B (zh) 干扰素α的干粉吸入剂
Kinnula et al. Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma
JPH02264730A (ja) Ａｔｌｌ治療用吸入剤
HU207229B (en) Process for producing pharmaceutical compositions containing gm-csf for treating leukocyte disfunction
Shah et al. An evaluation of two aerosol delivery systems for rhDNase
JPWO2005004914A1 (ja) ＮＦ−κＢデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法
US20210353650A1 (en) Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation
EP2627336A1 (fr) Procédé de traitement de la fibrose kystique avec du denufosol inhalé
Reiser et al. Inhalation treatment for asthma.
IE914444A1 (en) Administering alpha interferon by oral inhalation to treat¹asthma and non-malignant proliferative pulmonary diseases
Shaikh et al. Recent trends in applications of pulmonary drug delivery: a review
JP2759050B2 (ja) 突発性難聴治療用医薬組成物
Hockley et al. Fenoterol versus salbutamol nebulization in asthma
Douglas et al. A comparative study of two doses of salbutamol nebulized at 4 and 8 litres per minute in patients with chronic asthma
O′ Callaghan Targeting drug delivery to the lungs by inhalation
Laurenzi et al. Studies of Mucus Flow in the Mammalian Respiratory Tract: I. The Beneficial Effects of Acetyl Ouabain on Respiratory Tract Mucus Flow

Legal Events

Date Code Title Description
FZDE Discontinued